PeptidePlaza
The Free Peptide Reference

Atosiban

From PeptidePlaza, the free peptide reference · Entry #1032 · Anti-Aging · Sources fetched 2026-09-10 · Editorial standards

Atosiban (also known as Tractocile, Antocin, Antocin II, tractocil) is a anti-aging research peptide. Atosiban is an oxytocin receptor antagonist used to delay preterm labor. It is FDA-approved and acts by blocking the effects of oxytocin.

Atosiban is a synthetic peptide that functions as an oxytocin receptor antagonist. It works by competitively binding to oxytocin receptors in the myometrium, thereby inhibiting oxytocin-induced uterine contractions. This mechanism makes it useful in obstetrics to delay preterm birth. Atosiban has been approved by the FDA since 2000 for this indication. Research also explores its potential in conditions like endometriosis, and studies have investigated its role in optimizing embryo transfer in assisted conception. The literature includes randomized controlled trials on its efficacy for threatened preterm birth.

1 Mechanism of action

Oxytocin receptor antagonist (antagonist)

Primary targets: Oxytocin receptor

2 Reported effects

Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.

2.1 Indicated / studied for

  • Premature Birth
  • Endometriosis

3 Chemical and physical properties

CAS number90779-69-4
Molar mass994.2 g/mol
Purity (typical)Not independently verified
Storage−20 °C, lyophilised powder, desiccated
SolubilitySterile water / bacteriostatic water
Receptors / targetsOxytocin receptor

4 Research studies (8)

  1. Atosiban versus placebo for threatened preterm birth (APOSTEL 8): a multicentre, randomised controlled trial
    Lancet (London, England) (2025) · RCT
  2. Atosiban
    Clinical obstetrics and gynecology (1995) · Review
  3. Oxytocin Receptor Regulates the Hippo/YAP Axis to Drive Hepatocarcinogenesis
    Cancer research (2025)
  4. Interventions to optimize embryo transfer in women undergoing assisted conception: a comprehensive systematic review and meta-analyses
    Human reproduction update (2022) · Meta-Analysis
  5. Non-Cardiogenic Pulmonary Edema Due to Administration of Atosiban
    Cureus (2023) · Case Series
  6. Acute tocolysis
    Current opinion in obstetrics & gynecology (2005) · Review
  7. Maintenance tocolysis
    BJOG : an international journal of obstetrics and gynaecology (2005) · Meta-Analysis
  8. The oxytocin receptor
    Trends in endocrinology and metabolism: TEM (2003) · Review

5 Safety and risk profile

5.1 Regulatory status

Atosiban is currently classified as FDA approved. Approval applies to specific clinical indications and dosing; research-grade material is not the approved product.

Safety data disclaimer. Safety assessments are based on published literature and are for educational reference only. Clinical evidence varies significantly between peptides. Always consult primary research and current regulatory guidance.

6 Frequently asked questions

What is Atosiban used for?
Atosiban is primarily used to delay preterm birth by inhibiting uterine contractions. It has also been studied for its potential application in conditions such as endometriosis and in optimizing embryo transfer during assisted conception procedures.
How does Atosiban work?
Atosiban functions as an oxytocin receptor antagonist. It works by competitively binding to the oxytocin receptors in the uterus, which prevents oxytocin from stimulating uterine contractions. This action helps to relax the uterus and delay labor.
Is Atosiban FDA approved?
Yes, Atosiban is FDA approved. It received its first approval in the year 2000 for its use in managing threatened preterm birth, making it a recognized treatment option in obstetrics.
What class of drug is Atosiban?
Atosiban belongs to the class of drugs known as oxytocin receptor antagonists. This classification reflects its specific mechanism of action, where it blocks the activity of oxytocin at its receptors.

7 References

  1. Atosiban — compound summary PubChem. View source
  2. Atosiban — molecule record ChEMBL. View source
  3. Atosiban — published literature (571 records) PubMed. View source

Related compounds

Entries that share a target, a mechanism, or a research area with Atosiban.

Vasopressinapproved

Also anti-aging

Vasopressin is an FDA-approved peptide hormone and V1a, V1b, and V2 receptor agonist used to increase blood pressure in adults with vasodilatory shock.

Glutathioneanti-aging

Also anti-aging

The body's master antioxidant and the most abundant intracellular thiol. An unusual gamma peptide bond makes it resistant to normal peptidases — and its depletion tracks almost every disease of ageing.

Teriparatideapproved

Also anti-aging

The first drug that builds bone rather than merely slowing its loss — and it works only because it is given as a daily pulse. Continuous exposure to the same peptide destroys bone instead.

Desmopressinapproved

Also anti-aging

Desmopressin is a synthetic analog of vasopressin that acts as a vasopressin receptor agonist. It is FDA-approved for central diabetes insipidus and primary nocturnal enuresis.

Thymosinanti-aging

Also anti-aging

Thymosin is an endogenous human peptide that plays a role in cytoskeleton organization by binding to and sequestering actin monomers, thereby inhibiting actin polymerization.

VIPanti-aging

Also anti-aging

A 28-amino-acid neuropeptide with potent anti-inflammatory and immunomodulatory actions. Being studied for autoimmune diseases, type 2 diabetes, and antiviral applications.

8 See also

For research reference only. Not medical advice. Peptides may be regulated or restricted in your jurisdiction. Entry validated by the PeptidePlaza Biomedical Research Desk; see editorial standards.